还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

. N" y) L& S! s9 l                               
登录/注册后可看大图

请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

% y* H2 m' E  c* e可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
0 g* p! _, c( h

7 s1 L; Y0 _5 P4 Z3 kSub-category:
Molecular Targets
) J! [& _7 u# S  w7 P2 F. L
6 ?' R* y* {, n. y% P9 z  Q
/ v; `; V3 L7 TCategory:
Tumor Biology
0 \" z7 Q  W7 T2 \8 U

Meeting:
) Z# \, ]+ Q9 x- N2011 ASCO Annual Meeting
- A# G' V5 m7 K/ s! ]

Session Type and Session Title:
7 h6 x) H, y3 j1 g: ZPoster Discussion Session, Tumor Biology


Abstract No:
10517
; t) ?  s+ u& ^: y! |

$ M' e* g& n/ U/ HCitation:
" P) w/ Q, V8 g) [1 i, d  cJ Clin Oncol 29: 2011 (suppl; abstr 10517)


' |/ B( \: u) {' L; P$ lAuthor(s):
) G/ R! t0 ?8 X; h. T2 qJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China



2 ^2 D* h4 C$ z- z/ UAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.

Abstract Disclosures

Abstract:

3 L% V$ I& N  Q
9 W0 B7 z$ `/ U8 b( nBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

9 N: M$ T  [& k: _4 n: Z4 s" M                               
登录/注册后可看大图

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

+ o7 \/ N# w; v) q6 [                               
登录/注册后可看大图

  u, n7 I7 D0 l易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
ALK一个指标医院要900多 ...

平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？
6 t% g. f6 [0 S/ g* l1 V3 g# \
2 }1 {- c! }# X) V2 I现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊